Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

被引:51
作者
Heise, Tim [1 ]
Stender-Petersen, Kirstine [2 ]
Hoevelmann, Ulrike [1 ]
Jacobsen, Jacob Bonde [2 ]
Nosek, Leszek [1 ]
Zijlstra, Eric [1 ]
Haahr, Hanne [2 ]
机构
[1] Profil Inst Stoffwechselforsch GmbH, Hellersbergstr 9, D-41460 Neuss, Germany
[2] Novo Nordisk AS, Vandtarnsvej 114, DK-2860 Soborg, Denmark
关键词
GLYCEMIC CONTROL; VARIABILITY; GLARGINE; ANALOGS; HYPERGLYCEMIA; INJECTION; ONSET;
D O I
10.1007/s40262-016-0473-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Absorption of current rapid-acting insulins is too slow for patients with diabetes mellitus to achieve optimal postprandial glucose control. Faster-acting insulin aspart (faster aspart) is insulin aspart in a new formulation with faster early absorption. We compared the pharmacokinetic/pharmacodynamic properties of faster aspart and insulin aspart across a clinically relevant dose range. Methods In this randomised, double-blind, crossover trial, 46 subjects with type 1 diabetes mellitus received single subcutaneous doses of faster aspart and insulin aspart at 0.1, 0.2 (repeated three times to estimate within-subject variability) and 0.4 U/kg in a euglycaemic clamp setting (target 5.5 mmol/L). Results Consistently for the three doses, faster aspart demonstrated faster onset and greater early absorption and glucose-lowering effect versus insulin aspart. Across all three doses, onset of appearance occurred approximately twice as fast (approximately 5 min earlier) and early insulin exposure (AUC(IAsp,0-30min)) was approximately 1.5-to 2-fold greater for faster aspart versus insulin aspart. Likewise, onset of action occurred approximately 5 min faster and early glucose-lowering effect (AUC(GIR,0-30min)) was approximately 1.5- to 2-fold larger for faster aspart versus insulin aspart. Relative bioavailability was approximately 100% and total glucose-lowering effect was similar for faster aspart versus insulin aspart. Dose-concentration and dose-response relationships were comparable between faster aspart and insulin aspart. Within-subject variability in glucose-lowering effect was low for faster aspart (coefficient of variation approximately 20%) and not significantly different from insulin aspart. Conclusion The faster onset and greater early insulin exposure and glucose-lowering effect with faster aspart versus insulin aspart are preserved across a broad range of doses and consistently observed from day to day.
引用
收藏
页码:649 / 660
页数:12
相关论文
共 33 条
[1]  
[Anonymous], 2008, INSULIN, DOI [DOI 10.1016/S1557-0843(08)80010-3, 10.1016/s1557-0843(08)80010-3]
[2]   Clinical pharmacokinetics and pharmacodynamics of insulin glulisine [J].
Becker, Reinhard H. A. ;
Frick, Annke D. .
CLINICAL PHARMACOKINETICS, 2008, 47 (01) :7-20
[3]   Dose-response relationship of insulin glulisine in, subjects with type 1 diabetes [J].
Becker, Reinhard H. A. ;
Frick, Annke D. ;
Nosek, Leszek ;
Heinemann, Lutz ;
Rave, Klaus .
DIABETES CARE, 2007, 30 (10) :2506-2507
[4]  
Benesch Carsten, 2015, J Diabetes Sci Technol, V9, P792, DOI 10.1177/1932296815576957
[5]  
Bowering K, 2016, DIABETES, V65, pA63
[6]  
Childs BP, 2005, DIABETES CARE, V28, P1245
[7]   Bioequivalence and Comparative Pharmacodynamics of Insulin Lispro 200U/mL Relative to Insulin Lispro (Humalog®) 100 U/mL [J].
de la Pena, Amparo ;
Seger, Mary ;
Soon, Danny ;
Scott, Adam J. ;
Reddy, Shobha R. ;
Dobbins, Michael A. ;
Brown-Augsburger, Patricia ;
Linnebjerg, Helle .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (01) :69-75
[8]   REGULATION OF SPLANCHNIC AND PERIPHERAL GLUCOSE-UPTAKE BY INSULIN AND HYPERGLYCEMIA IN MAN [J].
DEFRONZO, RA ;
FERRANNINI, E ;
HENDLER, R ;
FELIG, P ;
WAHREN, J .
DIABETES, 1983, 32 (01) :35-45
[9]  
European Medicines Agency, 2010, CPMP/EWP/QWP/1401/ 98
[10]  
fda, Inactive ingredient search for approved drug products